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Methods: Two hundred and eighty patients with lung adenocarcinoma 
recurred who underwent pulmonary resection after 1997 at our institu-
tion. Since there were signiﬁcant bias in terms of potential prognostic 
factors between patients treated with and without geﬁtinib, we created 
pairs of cases (geﬁtinib treated patients: group A) and controls (treated 
without Geﬁtinib: group B) by matching gender, age, pathological 
stage, and smoking status. In this way we created 81 pairs of patients 
from 280. We compared clinicopathological factors and survivals 
between two groups.
Results: Between group A and B, there was no difference in terms of 
gender, age, pathological stage, and smoking status because of match-
ing procedure. There was a signiﬁcant difference in overall survival 
between two groups (MST 62.6 month vs. 40.9 months, P=0.015). 
When we compared recurrence free survival (RFS) and post-recurrence 
survival (PRS), there was signiﬁcant difference in PRS (MST 37.9 
month vs. 17.0 months, P<0.001) but not in RFS (MST 23.7 month vs. 
16.9 months, P=0.34).
Conclusions: Although it is desirable to prove clinical beneﬁt of 
geﬁtinib by prospective phase III trial, this present study strongly sug-
gested that geﬁtinib could improve survival of Japanese patients with 
adenocarcinoma of the lung than treatment without geﬁtinib.
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Background: Platelet Derived Growth Factor Receptor alpha (PDG-
FR-alpha) is involved in angiogenesis and its expression has been 
found in lung cancer. Preclinical models have shown that I inhibits 
PDGFR and may subsequently inhibit angiogenesis. The combina-
tion of an approved agent with an anti-angiogenesis inhibitor may 
improve efﬁcacy in the salvage setting. Second line D monotherapy 
for NSCLC produces a response rate of 8-10% and a median survival 
of 6-8 months. Weekly D had similar efﬁcacy compared with every 3 
week schedule with better tolerability. In addition, I + D have additive 
anticancer activity. We initiated a phase II trial of I +D to evaluate the 
efﬁcacy and safety of this regimen in recurrent NSCLC. The primary 
endpoint was response rate using Simon two-stage design. A total of 32 
patients is planned. 
Methods: Patients (pts)with pathologically conﬁrmed NSCLC, mea-
surable disease, no more than 1 previous platinum-based chemotherapy 
regimen, PS 0-1, clinically stable brain metastases and adequate organ 
function were eligible. Tumor samples, when available, were tested 
for PDGFR expression by immunohistochemistry. All pts received D 
30mg/m2 intravenously weekly x 3 every 4 weeks and oral I 600mg 
daily for 4 cycles. Non-progressors after 4 cycles continued with I 
alone for a total of 12 months or until progression. Tumor response was 
assessed every 2 cycles. 
Results: Currently we have enrolled 17 patients. A total of 26 cycles of 
combined I+D were given. Patient characteristics and toxicity data are 
described below. Efﬁcacy data is premature. 
Conclusion: I +D combination has been well tolerated in this relapsed 
population. A detailed toxicity, efﬁcacy and PDGFR analysis will be 
presented.
Number of patients enrolled 17
Median age (range) 67 (52-80) 
M:F 15:2
PS0 : PS 1 0:17
Adeno: Squamous: Other 5:3:8
> Grade 3 neutropenia 1
Grade 4 thrombocytopenia 1
> Grade 3 nonhematological toxicity  
(possibly, probably or deﬁnitely treatment related)* 12
* Grade 3: syncope (1), dyspnea (1), hypokalemia (1), cough (1), abdominal pain (1), edema (1), vascular 
embolism (1), rash (1), insomnia (1), hyponatremia (1); Grade 4: cardiovascular (1); Grade 5 death (1) 
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Background: Advances in the understanding of tumor biology have 
led to the identiﬁcation of many of the key molecular pathways that 
drive tumor growth. One such pathway is triggered by activation of 
the epidermal growth factor receptor (EGFR). Geﬁtinib, a inhibitor of 
EGFR tyrosine kinase, has demonstrated antitumor activity in patients 
with advanced non-small cell lung cancer (NSCLC) who have failed 
all prior treatment regimens. Recently it has been reported that geﬁtinib 
activate platelet and then activated platelet activate lymphocyte and 
monocyte and as a result cell immunity against tumor is raised. The aim 
of this study was to investigate whether peripheral lymphocyte subsets 
could change after treament with geﬁtinib in NSCLC patients.
Method: We prospectively studied 17 consecutive NSCLC patients 
treated with geﬁtinib who had previously received two chemotherapy 
regimens from March 2005 to May 2006. Before and after one and two 
months of treatment with geﬁtinib 30 ml of peripheral blood were ob-
tained and lymphocyte subset percentages which CD3+, CD4+, CD8+, 
CD19+, CD16+/56+ were checked by using ﬂowcytometry (Beckton-
Dickinson, USA).
Result: Before and after one and two months of treatment with geﬁ-
tinib, counts of WBC, lymphocyte and monocyte were not signiﬁcantly 
changed. Among the peripheral blood lymphocyte subsets, the percent-
age of CD8+ lymphocyte signiﬁcantly increased after two months of 
treatment with geﬁtinib. However, the percentages of other lymphocyte 
subsets were not signiﬁcantly changed.
Conclusion: This study suggests that geﬁtinib increase the percentage 
of CD8+ lymphocyte subset in NSCLC patients. Further studies on 
the effects of geﬁtinib on lymphocyte subsets in NSCLC patients are 
needed.
